New Skin Cancer Vaccine Trial Could Help Stop Melanoma Recurrence

New skin cancer vaccine trial could help stop melanoma recurrence

WASHINGTON, D.C. — A new vaccine paired with Merck's immunotherapy appeared to move closer to approval after a late-stage trial showed positive early results against the deadliest form of skin cancer.

Novel Cancer Vaccine Meets Primary, Secondary End Points in Resected Melanoma

Results from the INTERpath-001 trial of V0940 plus pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in resected melanoma.

expert reaction to top line results from the Phase 3 INTerpath-001 trial looking at an mRNA vaccine (intismeran) in combination with pembrolizumab for patients with completely resected stage IIB-IV melanoma

Scientists comment on phase 3 results from the INTerpath-001 trial looking at an mRNA vaccine for melanoma.    Sam Barrell, CEO of LifeArc, said: “These results are encouraging because they suggest treatments made for an individual patient, even in common conditions, may be moving closer to everyday clinical use. They indicate that highly personalised treatments can be developed, tested and potentially delivered on a much larger scale than previ…